title: Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?
authors: Genetic Epidemiology Group, Research Department of Epidemiology and Public Health, Division of Population Health,  University College London, Torrington Place, London WC1E 6BT,  UK.
authors: Aroon D
authors: AD
authors: Hingorani
authors: Reecha
authors: R
authors: Sofat
authors: Richard W
authors: RW
authors: Morris
authors: Peter
authors: P
authors: Whincup
authors: Gordon D
authors: GD
authors: Lowe
authors: Jennifer
authors: J
authors: Mindell
authors: Naveed
authors: N
authors: Sattar
authors: Juan P
authors: JP
authors: Casas
authors: Tina
authors: T
authors: Shah
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein